Clinical Trial Update: A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

View source ↗

Summary

A post-marketing survey evaluating the safety and effectiveness of Prezista (atazanavir) in patients with Acquired Immunodeficiency Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome

Drugs mentioned

• PREZISTA (darunavir)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Acquired Immune Deficiency Syndrome | Status: COMPLETED